scholarly journals Gd(iii)–Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

2020 ◽  
Vol 11 (9) ◽  
pp. 2524-2530 ◽  
Author(s):  
Casey J. Adams ◽  
Thomas J. Meade
Keyword(s):  
Mr Imaging ◽  
Contrast Agents ◽  
Contrast Enhancement ◽  
Theranostic Agents

The first example of Gd(iii)–Pt(iv) theranostic agents that are intracellularly reduced to provide MR contrast enhancement with simultaneous Pt(ii) chemotherapy.

Contrast agents for MR imaging of the liver: a clinical overview

1997 ◽  
Vol 7 (4) ◽  
pp. 507-513 ◽  
Author(s):  
A.-E. Mahfouz ◽  
B. Hamm ◽  
M. Taupitz
Keyword(s):  
Mr Imaging ◽  
Contrast Agents ◽  
Clinical Overview

scholarly journals Iron Oxide Nanoparticles as Theranostic Agents in Cancer Immunotherapy

Nanomaterials ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1950
Author(s):  
Rossella Canese ◽  
Federica Vurro ◽  
Pasquina Marzola
Keyword(s):  
Iron Oxide ◽  
Contrast Agents ◽  
Cancer Immunotherapy ◽  
Iron Oxide Nanoparticles ◽  
Imaging Techniques ◽  
Macrophage Polarization ◽  
Mri Contrast Agents ◽  
Oxide Nanoparticles ◽  
Diagnostic Potential ◽  
Theranostic Agents

Starting from the mid-1990s, several iron oxide nanoparticles (NPs) were developed as MRI contrast agents. Since their sizes fall in the tenths of a nanometer range, after i.v. injection these NPs are preferentially captured by the reticuloendothelial system of the liver. They have therefore been proposed as liver-specific contrast agents. Even though their unfavorable cost/benefit ratio has led to their withdrawal from the market, innovative applications have recently prompted a renewal of interest in these NPs. One important and innovative application is as diagnostic agents in cancer immunotherapy, thanks to their ability to track tumor-associated macrophages (TAMs) in vivo. It is worth noting that iron oxide NPs may also have a therapeutic role, given their ability to alter macrophage polarization. This review is devoted to the most recent advances in applications of iron oxide NPs in tumor diagnosis and therapy. The intrinsic therapeutic effect of these NPs on tumor growth, their capability to alter macrophage polarization and their diagnostic potential are examined. Innovative strategies for NP-based drug delivery in tumors (e.g., magnetic resonance targeting) will also be described. Finally, the review looks at their role as tracers for innovative, and very promising, imaging techniques (magnetic particle imaging-MPI).

Yolk–shell magnetic composite Fe3O4@Co/Zn-ZIF for MR imaging-guided chemotherapy of tumors in vivo

2021 ◽  
Author(s):  
Ying Li ◽  
Lu-Lu Jiang ◽  
Ya-Xian Qiao ◽  
Dong Wan ◽  
Yan-Feng Huang
Keyword(s):  
Mr Imaging ◽  
Contrast Enhancement ◽  
Magnetic Composite ◽  
Loading Capacity ◽  
Ph Responsive

The yolk–shell composites Fe3O4@Co/Zn-ZIF exhibited high doxorubicin loading capacity, pH-responsive release characteristics, and strong T2-weighted MR imaging contrast enhancement, and were used for MR imaging-guided chemotherapy of tumors in vivo.

Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison

2019 ◽  
Vol 119 ◽  
pp. 108633 ◽  
Author(s):  
Roberto Cannella ◽  
Giuseppe Brancatelli ◽  
Balasubramanya Rangaswamy ◽  
Marta I. Minervini ◽  
Amir A. Borhani ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Contrast Agents ◽  
Hepatocellular Adenoma ◽  
Enhancement Pattern ◽  
Intraindividual Comparison

Intraluminal contrast agents for MR imaging of the abdomen and pelvis

1994 ◽  
Vol 4 (3) ◽  
pp. 291-300 ◽  
Author(s):  
Tammo H. Pels Rijcken ◽  
Michael A. Davis ◽  
Pablo R. Ros
Keyword(s):  
Mr Imaging ◽  
Contrast Agents

scholarly journals Myocardial paramagnetic contrast agents for MR imaging

1988 ◽  
Vol 151 (5) ◽  
pp. 865-871 ◽  
Author(s):  
JJ Brown ◽  
CB Higgins
Keyword(s):  
Mr Imaging ◽  
Contrast Agents

Comparison of the Safety of Standard and Triple Dose Gadodiamide Injection in MR Imaging of the Central Nervous System

1994 ◽  
Vol 35 (4) ◽  
pp. 396-399 ◽  
Author(s):  
M. G. Svaland ◽  
T. Christensen ◽  
E. Lundorf
Keyword(s):  
Mr Imaging ◽  
Adverse Events ◽  
Contrast Enhancement ◽  
Dose Group ◽  
Serum Bilirubin ◽  
Diagnostic Yield ◽  
Blood Chemistry ◽  
New Information ◽  
Safety Parameters ◽  
The Central Nervous System

Gadodiamide injection was administered intravenously to 49 patients with known or suspected CNS lesions undergoing MR imaging. Two parallel groups were used to evaluate the efficacy and safety of single doses of 0.1 (25 patients) and 0.3 (24 patients) mmol/kg b.w. The principal measures of efficacy were diagnostic yield of MR and the overall contrast enhancement. Adverse events and serum bilirubin were the main safety parameters. Contrast enhancement of the lesion was observed for 16 patients in each dose group. Thirteen patients in the 0.1 and 17 in the 0.3 mmol/kg group had their diagnosis amended following the postcontrast image, but only one patient in each dose group had their management affected by new information from the postcontrast image. The overall diagnostic utility of gadodiamide injection was good, but there were no differences between the 2 doses studied in this respect. No injection-associated discomfort or other adverse events were reported. No clinically important changes in serum bilirubin, or other parameters of blood chemistry, or hematology were observed. Overall, the safety profile of gadodiamide injection 0.3 mmol/kg b.w. in this study was similar to that of 0.1 mmol/kg b.w.

Intrathecal administration of nitroxides as potential contrast agents for MR imaging.

Radiology ◽  
1987 ◽  
Vol 163 (1) ◽  
pp. 239-243 ◽  
Author(s):  
G M Rosen ◽  
L K Griffeth ◽  
M A Brown ◽  
B P Drayer
Keyword(s):  
Mr Imaging ◽  
Contrast Agents ◽  
Intrathecal Administration
Sign in / Sign up

Export Citation Format

Share Document